Botanix Wins Shareholder Backing for A$45m Capital Raising to Fund Sofdra Rollout

Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an announcement.

Botanix Pharmaceuticals has secured shareholder approval for all resolutions at its Extraordinary General Meeting, clearing the way for a previously announced capital raising to proceed. The package includes a two‑tranche placement totaling A$40 million and an underwritten Security Purchase Plan of A$5 million, alongside 1:1 options with a A$0.06 exercise price expiring in January 2027.

Shareholders approved the issue of new shares and options under the placement and SPP, with directors and the CEO committing about A$500,000 under Tranche 2, signaling internal confidence. Proceeds will fund API purchases and manufacturing, alternative supplier setup, marketing initiatives, operating expenses, working capital and transaction costs, supporting the commercial rollout and scaling of its dermatology portfolio, including Sofdra.

The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

More about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix that focuses on treatments for skin disorders. The company has received FDA approval for Sofdra, the first and only new chemical entity approved to treat primary axillary hyperhidrosis, offering a novel solution for patients with limited prior options.

Average Trading Volume: 12,604,511

Technical Sentiment Signal: Sell

Current Market Cap: A$88.72M

For a thorough assessment of BOT stock, go to TipRanks’ Stock Analysis page.